Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 154.75

+0.7%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (106)	1/12/1999 11:18:00 PM
From: Miljenko Zuanic	Read Replies (1) of 1834

Nigel: I hear first time for Caliper T, so do not know what to think about collaboration. 35 novel target assay for screening is impressive. However, hundreds of thousands compounds per day (how many compounds do NBIX have?, maybe 1-200K) is old phrase which immediately cool me off. Now. all what NBIX need is +4 MM compounds from PCOP libraries, identified lead, optimized and license to large pharma for big bucks. Business plan sound good. What will come out, who knows? I will like to hear about APL and LLY IND. Also, update from Novartis PD trials and J&J CRF antagonist progress. It will make me more excited. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next